Tudhope Susan J, Finney-Hayward Tricia K, Nicholson Andrew G, Mayer Ruth J, Barnette Mary S, Barnes Peter J, Donnelly Louise E
Airway Disease Section, Guy Scadding Building, National Heart and Lung Institute, Imperial College London, Dovehouse St., London SW3 6LY, UK.
J Pharmacol Exp Ther. 2008 Jan;324(1):306-12. doi: 10.1124/jpet.107.127670. Epub 2007 Oct 5.
Macrophages release cytokines that may contribute to the chronic inflammation observed in pulmonary conditions such as asthma and chronic obstructive pulmonary disease. Thus, inhibition of macrophage cytokine production may have a therapeutic benefit. Human lung macrophages are a rich source of the proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6, and IL-8, that are elevated in the bronchoalveolar lavage and sputum of subjects with respiratory diseases. Cytokine production from both monocytes and macrophages is mediated by mitogen-activated protein kinase (MAPK) pathways. This study compared the effects of a novel p38 MAPK inhibitor, N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)-guanidine (PCG), and an extracellular signal-regulated kinase (ERK) pathway inhibitor, 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD098059), on cytokine release from lipopolysaccharide (LPS)-stimulated human monocytes, monocyte-derived macrophages (MDM), and lung macrophages. Lung macrophages, MDM, and monocytes were stimulated with LPS, and cytokine release was measured by enzyme-linked immunosorbent assay. Immunoblots were performed to confirm p38 and ERK1/2 MAPK expression and activity. PCG inhibited TNF-alpha release more effectively from monocytes compared with MDM or macrophages (maximal inhibition was 99.3 +/- 1.4, 62.7 +/- 4.3, and 58.6 +/- 6.6%, respectively; n = 7-9). PD098059 was less effective at suppressing TNF-alpha release from monocytes compared with MDM and lung macrophages (maximal inhibition was 37.4 +/- 2.8, 70.1 +/- 4.5, and 68.7 +/- 5.1%, respectively; n = 7-9). The pattern of GM-CSF, IL-6, and IL-8 release was comparable with that of TNF-alpha. These data suggest a differential involvement for each of these MAPK pathways in macrophage cytokine production compared with monocytes.
巨噬细胞释放的细胞因子可能导致在诸如哮喘和慢性阻塞性肺疾病等肺部疾病中观察到的慢性炎症。因此,抑制巨噬细胞细胞因子的产生可能具有治疗益处。人肺巨噬细胞是促炎细胞因子的丰富来源,包括肿瘤坏死因子(TNF)-α、粒细胞巨噬细胞集落刺激因子(GM-CSF)、白细胞介素(IL)-6和IL-8,这些细胞因子在患有呼吸系统疾病的受试者的支气管肺泡灌洗物和痰液中水平升高。单核细胞和巨噬细胞的细胞因子产生由丝裂原活化蛋白激酶(MAPK)途径介导。本研究比较了一种新型p38 MAPK抑制剂N-氰基-N'-(2-{[8-(2,6-二氟苯基)-4-(4-氟-2-甲基苯基)-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-2-基]氨基}乙基)-胍(PCG)和细胞外信号调节激酶(ERK)途径抑制剂2-(2-氨基-3-甲氧基苯基)-4H-1-苯并吡喃-4-酮(PD098059)对脂多糖(LPS)刺激的人单核细胞、单核细胞衍生的巨噬细胞(MDM)和肺巨噬细胞释放细胞因子的影响。用LPS刺激肺巨噬细胞、MDM和单核细胞,并通过酶联免疫吸附测定法测量细胞因子释放。进行免疫印迹以确认p38和ERK1/2 MAPK的表达和活性。与MDM或巨噬细胞相比,PCG更有效地抑制单核细胞中TNF-α的释放(最大抑制分别为99.3±1.4%、62.7±4.3%和58.6±6.6%;n = 7 - 9)。与MDM和肺巨噬细胞相比,PD098059在抑制单核细胞中TNF-α释放方面效果较差(最大抑制分别为37.4±2.8%、70.1±4.5%和68.7±5.1%;n = 7 - 9)。GM-CSF、IL-6和IL-8的释放模式与TNF-α的模式相似。这些数据表明,与单核细胞相比,这些MAPK途径在巨噬细胞细胞因子产生中的参与存在差异。